These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 20086158

  • 21. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [Abstract] [Full Text] [Related]

  • 22. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H, Sáenz Y, Nichols WW, Tulkens PM, Van Bambeke F.
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [Abstract] [Full Text] [Related]

  • 23. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S, Ge Y, Livermore DM.
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [Abstract] [Full Text] [Related]

  • 24. Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
    Dupont H, Marciniak S, Zogheib E, Mammeri H, Friggeri A, Ammenouche N, Levrard M, Airapetian N, Tinturier F, Mahjoub Y.
    Anaesth Crit Care Pain Med; 2015 Jun; 34(3):141-4. PubMed ID: 26004874
    [Abstract] [Full Text] [Related]

  • 25. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M, Fàbrega A, Cobos-Trigueros N, Zamorano L, Ferrer-Navarro M, Ballesté-Delpierre C, Reustle A, Castro P, Nicolás JM, Oliver A, Martínez JA, Vila J.
    J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
    [Abstract] [Full Text] [Related]

  • 26. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN.
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [Abstract] [Full Text] [Related]

  • 27. In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa.
    Lomovskaya O, Rubio-Aparicio D, Nelson K, Sun D, Tsivkovski R, Castanheira M, Lindley J, Loutit J, Dudley M.
    Antimicrob Agents Chemother; 2021 May 18; 65(6):. PubMed ID: 33782010
    [Abstract] [Full Text] [Related]

  • 28. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
    Moyá B, Zamorano L, Juan C, Ge Y, Oliver A.
    Antimicrob Agents Chemother; 2010 Sep 18; 54(9):3933-7. PubMed ID: 20547785
    [Abstract] [Full Text] [Related]

  • 29. In vitro development of resistance against antipseudomonal agents: comparison of novel β-lactam/β-lactamase inhibitor combinations and other β-lactam agents.
    Castanheira M, Kimbrough JH, Lindley J, Doyle TB, Ewald JM, Sader HS.
    Antimicrob Agents Chemother; 2024 May 02; 68(5):e0136323. PubMed ID: 38526050
    [Abstract] [Full Text] [Related]

  • 30. Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa.
    Fournier D, Richardot C, Müller E, Robert-Nicoud M, Llanes C, Plésiat P, Jeannot K.
    J Antimicrob Chemother; 2013 Aug 02; 68(8):1772-80. PubMed ID: 23587654
    [Abstract] [Full Text] [Related]

  • 31. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA.
    Diagn Microbiol Infect Dis; 2002 Jul 02; 43(3):239-43. PubMed ID: 12106958
    [Abstract] [Full Text] [Related]

  • 32. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.
    Riera E, Macià MD, Mena A, Mulet X, Pérez JL, Ge Y, Oliver A.
    J Antimicrob Chemother; 2010 Jul 02; 65(7):1399-404. PubMed ID: 20435779
    [Abstract] [Full Text] [Related]

  • 33. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI).
    Antimicrob Agents Chemother; 2011 May 02; 55(5):1906-11. PubMed ID: 21357294
    [Abstract] [Full Text] [Related]

  • 34. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B.
    APMIS; 2005 Mar 02; 113(3):187-96. PubMed ID: 15799762
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Determination of extended spectrum beta-lactamases, metallo-beta-lactamases and AmpC-beta-lactamases among carbapenem resistant Pseudomonas aeruginosa isolated from burn patients.
    Neyestanaki DK, Mirsalehian A, Rezagholizadeh F, Jabalameli F, Taherikalani M, Emaneini M.
    Burns; 2014 Dec 02; 40(8):1556-61. PubMed ID: 24767143
    [Abstract] [Full Text] [Related]

  • 37. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM, Chen HY.
    J Antimicrob Chemother; 1997 Sep 02; 40(3):335-43. PubMed ID: 9338484
    [Abstract] [Full Text] [Related]

  • 38. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.
    Peña C, Suarez C, Tubau F, Juan C, Moya B, Dominguez MA, Oliver A, Pujol M, Ariza J.
    J Clin Microbiol; 2009 Aug 02; 47(8):2381-7. PubMed ID: 19494059
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.